: iStockAnalyst.com Symbols Feed

Sangamo Biosciences (NASDAQ:SGMO): Shares Should Trade To A Range Of $10-11

Mon, 22 Jun 2009 13:10:54 GMT

Merriman Curhan Ford is out with a rather positive call on Sangamo Biosciences (NASDAQ:SGMO) reiterating their Buy rating and raising their target range from $5.50-6.50 to $10-11. Firm believes Sangamo has the potential to be the leader in zinc finger applications both in the therapeutic arena and applications outside of the clinic. While the company’s diabetic neuropathy program is currently in question, they still believe in the therapeutic potential for the zinc finger platform. Additionally, partnerships with Dow Agro- Sciences and Sigma-Aldrich have the potential to provide Sangamo with future royalty streams and milestone payments. Merriman believes SGMO shares should trade to a range of $10-11. Broad growth opportunity. Sangamo is now entering an interesting[More...]

Sangamo Biotech a Strong Buy

Fri, 10 Oct 2008 19:26:00 GMT

Sangamo Biosciences, Inc. (SGMO) is a biopharmaceutical company engaging in designing and developing engineered transcription factors for gene regulation. The company uses a proprietary gene regulation technology to discover and develop a new class of therapeutic candidates for cardiovascular disease, cancer, neuropathic pain and immune diseases, such as sickle cell anemia and HIV. Sangamo uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases. We are optimistic about this novel technology and are encouraged to hear that the company intends to bring more drug candidates into the clinic in 2008. We are also impressed by the company's strategy to monetize this ZFP technology. We maintain our Buy rating on[More...]

Analyst Comments: Sangamo Bioscience, CryoLife, Progressive, EnCana, Linear Tech, Cosi

Fri, 11 Jul 2008 18:19:00 GMT

We are optimistic about Sangamo Biosciences Inc.'s (SGMO) unique zinc finger DNA-binding protein (ZFP) technology and are encouraged to hear that the company intends to bring more drug candidates into the clinic in 2008. We are also impressed by the company's strategy to monetize this ZFP technology. Sangamo has signed agreements with Dow AgroSciences (DOW),...[More...]

Jobless Claims, Oil Prices & Healthcare

Thu, 19 Jun 2008 14:19:59 GMT

Good morning. Premarket futures are showing a slight positive bias following a dip in weekly jobless claims and oil prices.[More...]

Analyst Comments: Lithia, Exar, OPNET, Sangamo, Baxter, Castle Brands

Tue, 22 Apr 2008 13:57:31 GMT

Lithia Motors, Inc. (LAD) is a growing retailer in the highly fragmented automotive industry. The company is focused on improving productivity, which should propel earnings growth. Our major concerns are the general health of the overall industry, exposur[More...]

Analyst Comments: Sangamo Biosciences, Hitachi, Allot Communications, Philips

Wed, 06 Feb 2008 17:21:48 GMT

Sangamo Biosciences, Inc. (SGMO) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer, and immune diseases. We are optimistic about this nov[More...]

Retail Sales, Subprime, Rates & Jobs

Thu, 06 Dec 2007 14:09:51 GMT

Good morning. Premarket futures have been volatile (turning from positive to just negative ahead of the open) and most likely suggestive of the day ahead. News that Bush will freeze interest rates for up to five years for some subprime borrowers and an interest rate cut by the Bank of England (the European Central Bank kept interest rates at 4%) are topping the headlines. In addition,...[More...]

Pre-Market - Wednesday July 11th

Thu, 12 Jul 2007 20:32:14 GMT

Gapping down on weak earnings/guidance: VTAL -24.3%, CPWR -17.8%, HITK -6.2%, RYL -4.7%, INFY -2.3%... Other news: DNDN -6.1% (disclosed the SEC is conducting an informal probe related to the clinical trials for Provenge), ANAD -3.0% (downgraded to Neutral at Credit Suisse), JSDA -3.0% (still checking), JASO -2.8% (downgraded to Hold at Needham), ATVI -1.6% (downgraded to Neutral at JP Morgan). Gapping up on strong earnings/guidance: ACGY +8.3%... M&A: BCGI +70.9% (to be acquired by Megasoft for $3.60 per share), CHAP +10.5% (to be acquired by Gerdau Ameristeel for $86.00 per share)... Other news: TRCA +22.7% (announces agreement with Genentech for worldwide growth hormone...[More...]